期刊文献+

北京市2007年慢性维持性血液透析患者钙磷代谢分析 被引量:56

Analysis the calcium and phosphorus metabolism disorders in Beijing chronic maintenance hemodialysis patients
下载PDF
导出
摘要 目的分析北京市在透的血液透析患者钙磷代谢状况,寻找存在的问题,提出改进建议。方法以KDOQI指南为依据,分析2007年北京市在透析的血液透析患者校正的血钙、血磷、钙磷乘积和全段iPTH的水平、达标率,及其在不同年龄、性别的分布情况,并与DOPPS Ⅱ期和Ⅲ期结果相比较。结果2007年北京市在透析血液透析患者校正的血钙、血磷、钙磷乘积和iPTH的达标率分别为53.6%、50.2%、71.3%和28.5%。除了血iPTH外,其他指标均好于2006年和2005年。校正的血钙、血磷、钙磷乘积和iPTH四项指标中1项达标占17.3%,2项达标占27.3%,3项达标占32.9%,四项均达标占16.7%。与DOPPS Ⅱ期研究结果比较,单项和四项达标率好于DOPPSⅡ期结果。结论有相当比例的血液透析患者未能满意的控制钙磷代谢紊乱及其继发性甲状旁腺功能亢进,有待于我们的进一步努力。 Objective Abnormalities in serum calcium, phosphorus and parathyroid hormone (PTH) con- centrations are common in patients with hemodialysis patients and have been associated with increased morbidity and mortality. Clinical trials have been conducted to clearly identify categories of calcium, phosphorus and iPTH levels associated with the cardiovascular (CVD) risk. We compare calcium, phosphorus and iPTH levels of liD patients that provided by Beijing Dialysis Outcomes and Practisce survey in 2007 with DOPPS (the international trends in the Dialysis Outcomes and Practice Patterns Study, an international study of hemodialysis practices and associated outcomes), in order to realize the calcium and phosphorus metabolism of liD patients in Beijing. Methods Analysis the data of serum calcium, phosphorus and iPTH levels of HD patients in Beijing in 2007. Results Categories of serum calcium during 2.11 ~2.37mmol/L pre-HD presents 51.6%, serum phosphorus during 1.13 ~1.78mmol/L pre- HD presents 50.2%, Ca×P product lower than 55 mg2/dL2 presents 71.3% and level of iPTH during 150-300pg/ml presents 28.5% of all. All four items up to par present 16.7% in 2007, compared with DOPPS Ⅱ data (5.5%). Conslusions There are more HD patients who had abnormal mineral metabolism and secondary hyperparathyroidism, we should pay more attention to them.
作者 李月红 王梅
出处 《中国血液净化》 2010年第2期112-115,共4页 Chinese Journal of Blood Purification
基金 北京大学人民医院研究与发展基金资助项目(基金编号:RDC2009-14 项目号:802045)
关键词 血液透析 校正血钙 血磷 甲状旁腺素 DOPPS Hemodialysis albumin-corrected calcium serum phosphorus iPTH levels DOPPS
  • 相关文献

参考文献9

  • 1Kimata N, Albert JM, Akiba T, et al. Association of mineral metabolism factors with all cause and cardiovascular mor tality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study[J].Hemodial Int, 2007, 11:340-348.
  • 2Wald R, Tentori F, Tighiouart H, et al. Impact of the Kidney Disease outcomes Quality Initiative(KDOQI)Clinical practice Guidelines for Bone Metabolism and Disease in a large dialysis network[J].Am I Kidney Dis, 2007,49:257 266.
  • 3Tentori F, Blayney MJ, Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)[J].Am J Kidney Dis, 2008, 52:519- 530.
  • 4Mendelssohn DC, Pisoni RL, hrrington CJ, et al.A practice- related risk score (PRS): A DOPPS-derived aggregate qual ity index for haemodialysis facilities[J].Nephrol Dial Transplant, 2008,23:3227-3233.
  • 5王海燕,王梅主译.慢性肾脏病及透析的临床实践指南[M].北京人民卫生出版社,2003,89.
  • 6王梅.维持性血液透析患者钙磷代谢紊乱的机制与处理对策[J].中国实用内科杂志,2007,27(22):1747-1749. 被引量:15
  • 7Block GA, Klassen PS, LazarusJM, et al. Mineralmetabolism, mortality, and morbidity in maintenance hemodialysis[J]. J Am Soc Nephrol,2004,15:2208 2218.
  • 8Chertow GM, Raggi P, Chasan Tabar S, et al. Determinants of progressive vascular calcification in hemodia]ysis patients [J]. Nephrol Dial Transplant, 2004,19:1489-1496.
  • 9~ang H, Curinga G, Giachelli CM. Elevated extracellular cal cium levels induce smooth muscle cell matrix mineraliza tion in vitro[J]. Kidney Int, 2004,66:2293-2299.

二级参考文献11

  • 1孙鲁英,王梅,杨莉.终末期肾脏病患者钙磷代谢及甲状旁腺激素水平的临床分析[J].北京大学学报(医学版),2005,37(2):147-150. 被引量:63
  • 2Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients[J]. Am J Kidney Dis,1996,27 : 394 -401.
  • 3Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysls patients :a national study [J]. Am J Kidney Dis, 1998,31 : 607 -617.
  • 4Raggi P, Boulay A, Chasan Taber S, et al. Cardiac calcification in adult hemodialysis patients, a link between end-stage renal disease and cardiovascular disease? [ J ]. J Am Coll Cardiol, 2002,39 (4) : 695 -701.
  • 5Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J]. Kidney Int,2002,62( 1 ) : 245 -252.
  • 6Haese PC, Spasovski GB, Sikole A, et al. A muhicenter study on the effects of lanthanum carbonate( Fosrenol TM)and calcium carbonate on renal bone disease in dialysis patients [J]. Kidney Int, 2003, (Suppl) 85 : 73 - 88.
  • 7Chertow GM, Raggi P, Chasan-Tabar S, et al. Determinants of progressive vascular calcification in hemodialysis patients [J]. Nephrol Dial Transplant ,2004,19 : 1489 - 1496.
  • 8Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro [J]. Kidney Int,2004,66(6) : 2293 -2299.
  • 9Block GA, Klassen PS, Lazarus JM ,et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis [J]. J Am Soc Nephrol,2004,15 (8): 2208-2218.
  • 10Slatopolsky E, Finch J, Brown A. New vitamin D analogs [ J ]. Kidney Int,2003, (Suppl) 85 : 83 - 87.

共引文献14

同被引文献519

引证文献56

二级引证文献511

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部